

# Alexander M Lila

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5300028/alexander-m-lila-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79  
papers

230  
citations

7  
h-index

13  
g-index

91  
ext. papers

283  
ext. citations

0.7  
avg, IF

4.15  
L-index

#	Paper	IF	Citations
79	Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate. <i>Farmakoekonomika</i> , <b>2022</b> , 14, 537-547	1.1	7
78	Medical and social significance and calculation of the economic burden of axial spondyloarthritis in the Russian Federation. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 20-25	0.7	1
77	Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 38-45	0.7	
76	Important aspects of osteoarthritis therapy during the COVID-19 pandemic. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 108-114	0.7	
75	Fibromyalgia in rheumatoid arthritis: features of pain syndrome, impact on disease activity and quality of life of patients. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 32-37	0.7	
74	Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2022</b> , 60, 21-31	0.9	4
73	Treatment of patients with systemic lupus erythematosus without glucocorticoids [myth or reality?]. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 77-83	0.7	
72	Advances in rheumatology at the beginning of the 21st century. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2022</b> , 60, 5-20	0.9	
71	Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate. <i>Farmakoekonomika</i> , <b>2022</b> , 15, 162-169	1.1	1
70	Therapeutic potential of a drug based on avocado and soy unsaponifiable compounds in the treatment of osteoarthritis: data from Russian and international studies (descriptive review). <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 48-55	0.7	
69	Systematic review and meta-analysis: risk factors for psoriatic arthritis. Part 2. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 26-33	0.7	
68	Symptomatic delayed-acting drugs (SYSADOA): new applications. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 99-106	0.7	1
67	Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the "central" manifestations of pain. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 34-42	0.7	1
66	Analysis of the mechanisms of development of neuro-rheumatological consequences of COVID-19 and the possibility of their pharmacological correction. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 92-98	0.7	1
65	Clinical significance of antibodies to the phosphatidylserine/prothrombin complex. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 81-86	0.7	
64	Intra-articular glucocorticoid injection site: best practice guidelines. <i>Meditinskiy Sovet</i> , <b>2021</b> , 155-162	0.4	
63	Extra-criteria antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 18-25	0.7	1

62	Pharmacoinformation studies of chondroprotectors. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 114-120	0.7	0
61	Determination of the accuracy of osteoporotic fractures risk assessment in patients with rheumatoid arthritis using the prognostic model, developed at V.A. Nasonova Research Institute of Rheumatology, and the FRAX algorithm. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 51-56	0.7	
60	Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 68-75	0.7	2
59	Difficult-to-treat rheumatoid arthritis. What is it?. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 7-11	0.7	2
58	Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 96-102	0.7	
57	Evaluation of the effectiveness of intra-articular administration of highly purified hyaluronic acid in knee osteoarthritis in real clinical practice. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 57-61	0.7	
56	Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 47-55	0.9	1
55	COVID-19 and rheumatology: A year later. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 31-36	0.9	7
54	Dynamics of traditional modifiable risk factors, total cardiovascular risk, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 84-92	0.9	
53	T- and B-lymphocytes subpopulations in the early and advanced rheumatoid arthritis. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 17-22	0.7	
52	Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status. <i>Farmakoekonomika</i> , <b>2021</b> , 14, 28-39	1.1	6
51	Osteoarthritis background therapy: current view on the glucosamine and chondroitin therapy. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 112-119	0.7	2
50	Contribution of neurogenic mechanisms to the pathogenesis of chronic joint pain. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 43-49	0.7	3
49	Use of tanezumab for chronic pain treatment. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 192-200	0.9	1
48	Use of magnetotherapy in complex treatment and rehabilitation of patients with osteoarthritis (based on consensus of specialists for therapists and general practitioners of polyclinics). <i>Medical Alphabet</i> , <b>2021</b> , 31-35	0.3	
47	Forecasting index of unfavorable outcomes of systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 98-102	0.7	0
46	Comprehensive approach to the choice of therapy in patients with osteoarthritis at the first visit to the doctor. Expert consensus (literature review and resolution). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 111-116	0.7	1
45	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 239-254	0.9	26

44	Post-COVID syndrome—The focus is on musculoskeletal pain. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 255-262	0.9	5
43	Psychiatric aspects of spondyloarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 58, 716-724	0.9	0
42	Efficiency and safety of magnetotherapy in the treatment of osteoarthritis. Expert council (3 June 2020, Moscow). <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 58, 734-742	0.9	0
41	Remote monitoring of patients with axial spondyloarthritis during the COVID-19 pandemic: results and prospects of using the information technology «spine» <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 58, 683-690	0.9	2
40	Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 136-143	0.7	5
39	The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 9-14	0.7	
38	Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 66-72	0.7	
37	Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. <i>Farmakoekonomika</i> , <b>2021</b> , 13, 388-399	1.1	28
36	The role of microbiome in the pathogenesis of immune-mediated inflammatory diseases: controversial issues. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 15-19	0.7	
35	Thromboembolic complications in antiphospholipid syndrome and ankylosing spondylitis (two clinical cases). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 98-104	0.7	
34	Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 120-125	0.7	2
33	Satisfaction with analgesic therapy in patients with rheumatic diseases in real clinical practice, according to the KOMPAS study (Quality of Pain Relief in the Opinion of Patients with Arthritis and Back Pain). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 43-49	0.7	2
32	Combination of ankylosing spondylitis with combined autoinflammatory skin lesions (clinical observation and literature review). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 81-86	0.7	
31	Resolution of the Expert Council «The role of type I interferon inhibitor in the treatment of patients with systemic lupus erythematosus». <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 126-128	0.7	
30	Assessment of the activity and organ damage in antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 101-106	0.7	
29	Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 87-93	0.7	
28	Molecular basis for new approaches to therapy of osteoarthritis (part I). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 7-12	0.7	
27	The use of biosimilars as a new approach to the treatment of rheumatoid arthritis. <i>Meditinskiy Sovet</i> , <b>2021</b> , 112-121	0.4	

26	Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). <i>Klinicheskaya Laboratornaya Diagnostika</i> , <b>2021</b> , 66, 546-551	0.5	
25	Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 367-383	0.9	3
24	Insulin resistance and type 2 diabetes mellitus risk factors in systemic lupus erythematosus. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 406-410	0.9	
23	Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 38 months. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 394-400	0.9	2
22	Comparison of standard radiography and magnetic resonance imaging in hand osteoarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 418-425	0.9	
21	Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 58, 631-636	0.9	3
20	Analysis of the factors determining the development of postoperative pain in patients after knee and hip replacement surgery. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 19-25	0.7	
19	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 76-83	0.7	1
18	Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 59, 666-675	0.9	6
17	Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 111-116	0.7	
16	EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II). <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 214-224	0.9	6
15	BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 304-316	0.9	9
14	DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 340-343	0.9	5
13	Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system. <i>Farmakoekonomika</i> , <b>2020</b> , 13, 23-34	1.1	10
12	ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 225-231	0.9	2
11	Is there an alternative to diclofenac i/m injections for rapid relief of severe pain? Results of randomized controlled and partially blind forsage study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 387-394	0.9	1
10	The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 532-543	0.9	5
9	Comparison of the effectiveness of subacromial administration of platelet-rich plasma and hyaluronic acid in chronic shoulder pain caused by damage to the tendons of the rotator cuff muscles according to a 6-month open clinical study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 570-576	0.9	

8	Safe therapy of osteoarthritis: place of topical nonsteroidal anti-inflammatory drugs. <i>Meditinskiy Sovet</i> , <b>2020</b> , 128-134	0.4	3
7	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 353-367	0.9	19
6	Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 456-462	0.9	5
5	Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2020</b> , 58, 480-488	0.9	6
4	Efficacy and safety of two <i>Qarmolis</i> forms for combined local therapy of knee osteoarthritis: results of a multicenter clinical trial. <i>Klinicist</i> , <b>2020</b> , 14, 100-106	0.3	
3	Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis?. <i>Farmakoekonomika</i> , <b>2020</b> , 13, 184-191	1.1	10
2	Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts opinion. <i>Al?manah Klinicheskoy Meditsiny</i> , <b>2020</b> , 48, 422-436	0.2	5
1	A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. <i>Rheumatology International</i> , <b>2019</b> , 39, 1537-1546	3.6	5